Your browser doesn't support javascript.
loading
Cardiometabolic biomarker patterns associated with cardiac MRI defined fibrosis and microvascular dysfunction in patients with heart failure with preserved ejection fraction.
Siggins, Connor; Pan, Jonathan A; Löffler, Adrián I; Yang, Yang; Shaw, Peter W; Balfour, Pelbreton C; Epstein, Frederick H; Gan, Li-Ming; Kramer, Christopher M; Keeley, Ellen C; Salerno, Michael.
Afiliación
  • Siggins C; Department of Chemistry, University of Virginia, Charlottesville, VA, United States.
  • Pan JA; Cardiovascular Division, Department of Medicine, University of Virginia Health System, Charlottesville, VA, United States.
  • Löffler AI; UCHealth Heart and Vascular Clinic, Greeley Medical Center, Greeley, CO, United States.
  • Yang Y; BioMedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, United States.
  • Shaw PW; New England Heart and Vascular Institute, Catholic Medical Center, Manchester, NH, United States.
  • Balfour PC; Baptist Heart & Vascular Institute, Baptist Health Care, Pensacola, FL, United States.
  • Epstein FH; Department of Biomedical Engineering, University of Virginia, Charlottesville, VA, United States.
  • Gan LM; Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.
  • Kramer CM; Cardiovascular Division, Department of Medicine, University of Virginia Health System, Charlottesville, VA, United States.
  • Keeley EC; Department of Radiology and Medical Imaging, University of Virginia Health System, Charlottesville, VA, United States.
  • Salerno M; Department of Medicine, University of Florida, Gainesville, FL, United States.
Front Cardiovasc Med ; 11: 1334226, 2024.
Article en En | MEDLINE | ID: mdl-38500750
ABSTRACT

Introduction:

Heart failure with preserved ejection fraction (HFpEF) is a complex disease process influenced by metabolic disorders, systemic inflammation, myocardial fibrosis, and microvascular dysfunction. The goal of our study is to identify potential relationships between plasma biomarkers and cardiac magnetic resonance (CMR) imaging markers in patients with HFpEF.

Methods:

Nineteen subjects with HFpEF and 15 age-matched healthy controls were enrolled and underwent multiparametric CMR and plasma biomarker analysis using the Olink® Cardiometabolic Panel (Olink Proteomics, Uppsala, Sweden). Partial least squares discriminant analysis (PLS-DA) was used to characterize CMR and biomarker variables that differentiate the subject groups into two principal components. Orthogonal projection to latent structures by partial least squares (OPLS) analysis was used to identify biomarker patterns that correlate with myocardial perfusion reserve (MPR) and extracellular volume (ECV) mapping.

Results:

A PLS-DA could differentiate between HFpEF and normal controls with two significant components explaining 79% (Q2 = 0.47) of the differences. For OPLS, there were 7 biomarkers that significantly correlated with ECV (R2 = 0.85, Q = 0.53) and 6 biomarkers that significantly correlated with MPR (R2 = 0.92, Q2 = 0.32). Only 1 biomarker significantly correlated with both ECV and MPR.

Discussion:

Patients with HFpEF have unique imaging and biomarker patterns that suggest mechanisms associated with metabolic disease, inflammation, fibrosis and microvascular dysfunction.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Front Cardiovasc Med Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Front Cardiovasc Med Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos
...